Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5350042 | 0.97 | TLR7 (0.70) | TLR7TLR8 | |
| SCHEMBL20796979 | 0.88 | TLR7 (0.60) | TLR7TLR8 | |
| SCHEMBL5119111 | 0.86 | TLR7 (0.57) | TLR7TLR8 | |
| SCHEMBL3172919 | 0.85 | TLR7 (0.78) | TLR7TLR8 | |
| SCHEMBL20623370 | 0.84 | TLR7 (0.89) | TLR7TLR8 | |
| SCHEMBL34467705 | 0.83 | TLR7 (0.66) | TLR7TLR8 | |
| SCHEMBL10147925 | 0.83 | TLR7 (0.84) | TLR7TLR8 | |
| SCHEMBL3167829 | 0.83 | TLR7 (0.68) | TLR7TLR8 | |
| SCHEMBL1951699 | 0.82 | TLR7 (0.93) | TLR7TLR8 | |
| SCHEMBL20647697 | 0.82 | TLR7 (0.74) | TLR7TLR8 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20130225555-A1 | Imidazoquinolines with Immuno-Modulating Properties | DAINIPPON SUMITOMO PHARMA CO., LTD. (JP) | 2013-08-29 | — | — | US | disclosed |
| US-8436178-B2 | Imidazoquinolines with immuno-modulating properties | ASTRAZENECA AB (SE) | 2013-05-07 | — | — | US | disclosed |
| EP-2155743-B1 | IMIDAZOQUINOLINES WITH IMMUNO-MODULATING PROPERTIES | ASTRAZENECA AB (SE) | 2012-08-29 | — | — | EP | disclosed |
| US-20100280001-A1 | IMIDAZOQUINOLINES WITH IMMUNO-MODULATING PROPERTIES | SUMITOMO DAINIPPON PHARMA CO., LTD. (JP) | 2010-11-04 | — | — | US | disclosed |
| EP-2155743-A1 | IMIDAZOQUINOLINES WITH IMMUNO-MODULATING PROPERTIES | AstraZeneca AB (SE) | 2010-02-24 | — | — | EP | disclosed |
| WO-2008135791-A1 | IMIDAZOQUINOLINES WITH IMMUNO-MODULATING PROPERTIES | ASTRAZENECA AB (SE) | 2008-11-13 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100280001-A1 | IMIDAZOQUINOLINES WITH IMMUNO-MODULATING PROPERTIES | IFNG, FCGRT, IFNAR1 | TLR7 267/4885TLR8 1392/4885 |
| US-20130225555-A1 | Imidazoquinolines with Immuno-Modulating Properties | IFNG, FCGRT, IFNAR1 | TLR7 267/4885TLR8 1392/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.